Full video transcriptClick to expand
Auto-generated transcript of @mjferreiraa's video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.
- 0:00That's why I found the one who was a being on the other,
- 0:02who lost 2,000 men and 3 babies,
- 0:05and I was really happy that she had a very good dream
- 0:08with 3,000 women.
- 0:09There's less than 3,000 men.
- 0:11My own dream was to be a loving partner,
- 0:13but that's why I wanna go to Galleria.
- 0:16You can follow my friends and friends.
- 0:18You can follow my friends and friends and friends.
- 0:21Now, I'll tell her my best best friend,
- 0:23who I've ever met.
- 0:24I'll talk about her and what I want to write to her.
- 0:27for some age.
- 0:39and the people who have been in this…
- 0:41that's why we're not going to touch the house
- 0:43for themselves, and that is just on the way.
- 0:46I want to take a look at what we are going to do
- 0:48and in the end we have to put on a pleasure,
- 0:50because there are things we need to do
- 0:52and that is what we're trying to do with the balance,
- 0:54and we are going to build a good,
- 0:56and that is one way to build us.
- 0:58I think we have to get out of that way.
- 0:59We're going to build it in the same way
- 1:02for some place where we can build our own buildings.
- 1:04You can't take a while, but it's not the same.
- 1:08It's about to be awesome.
- 1:09You can't take one of the kids.
- 1:10You can't take two of the kids.
- 1:13You can't take two of the kids.
Ozempic babies: what the fertility claims actually show
Quick answer
This video appears to discuss the emerging clinical phenomenon of unintended pregnancies in women using GLP-1 receptor agonists, likely driven by restored ovulation in women with PCOS and possible reduction in oral contraceptive efficacy due to slowed gastric emptying. The transcript is too garbled to extract direct medical claims, but the hashtag context points to semaglutide's off-label reproductive effects. Semaglutide carries a pregnancy avoidance warning and should be discontinued at least two months before planned conception per current clinical guidance.
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
Compounded Semaglutide access requires the right clinical path
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 6 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For Ozempic babies: what the fertility claims actually show, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Primary STEP 1 trial source for semaglutide weight-management efficacy and adverse-event context.
PubMed
Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance
Used for maintenance, discontinuation, and weight-regain discussions after semaglutide response.
PubMed
Tirzepatide Once Weekly for the Treatment of Obesity
Primary SURMOUNT-1 trial source for tirzepatide weight-loss ranges and tolerability.
PubMed
Continued Treatment With Tirzepatide for Maintenance of Weight Reduction
Used for continuation, stopping, and maintenance questions after initial weight loss.
PubMed
Provider decision path
Use local research to choose a safer review path
Direct answer
Compounded Semaglutide is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.
Evidence check
Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.
Safety check
Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.
Next step
When you are ready, the get-started flow can collect the details needed for a prescription review instead of leaving you to guess.
Claim path
Keep researching this semaglutide video claims cluster
Best for searchers comparing social semaglutide claims with GLP-1 eligibility, outcomes, and safety context.
Page-specific review note
What this exact clip is really saying
This FormBlends review is specific to "Ozempic babies: what the fertility claims actually show" from Maju Ferreira. We read the clip as a GLP-1 social video fact-checks claim about Compounded Semaglutide, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: This video appears to discuss the emerging clinical phenomenon of unintended pregnancies in women using GLP-1 receptor agonists, likely driven by restored ovulation in women with PCOS and possible reduction in oral contraceptive efficacy due to slowed gastric emptying.
The reason this review is not generic is the source wording and the canonical claim label "glp1 ozempic babies ozempic gravidez." In this clip, the useful excerpt is: "That's why I found the one who was a being on the other, who lost 2,000 men and 3 babies, and I was really happy that she had a very good dream with 3,000 women." That wording changes the review because it points to Compounded Semaglutide safety, access, evidence, and fit, not a one-size-fits-all protocol.
The source trail for this page is checked against Once-Weekly Semaglutide in Adults with Overweight or Obesity (2021), Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance (2021), and Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight (2022), plus the creator's own wording. Compounded Semaglutide still needs an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.
Claim verdict
The useful answer behind this video
This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.
Claim being checked
This video appears to discuss the emerging clinical phenomenon of unintended pregnancies in women using GLP-1 receptor agonists, likely driven by restored ovulation in women with PCOS and possible reduction in oral contraceptive efficacy due to slowed gastric emptying.
FormBlends verdict
Compounded Semaglutide safety, access, evidence, and fit
Evidence strength
Source-backed review with clinical or regulatory citations.
Patient-safe next step
Compare the claim with the Compounded Semaglutide guide, safety notes, access rules, and a licensed-provider review.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- This video appears to discuss the emerging clinical phenomenon of unintended pregnancies in women using GLP-1 receptor agonists, likely driven by restored ovulation in women with PCOS and possible reduction in oral contraceptive efficacy due to slowed gastric emptying. The transcript is too garbled to extract direct medical claims, but the hashtag context points to semaglutide's off-label reproductive effects. Semaglutide carries a pregnancy avoidance warning and should be discontinued at least two months before planned conception per current clinical guidance.
- The transcript from this video is likely corrupted by auto-captions translating Portuguese speech into English, making direct claim verification impossible.
- A 2024 study in JAMA Internal Medicine (Mojtabai et al.) found a statistically significant increase in unintended pregnancies among women taking GLP-1 agonists compared to matched controls on other anti-obesity medications.
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- Compounded Semaglutide decisions still need source quality, legal access, and provider oversight checks.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against the Compounded Semaglutide guide, cost path, safety notes, and provider review before acting.
Review Compounded SemaglutideWhat You'll Learn
- The transcript from this video is likely corrupted by auto-captions translating Portuguese speech into English, making direct claim verification impossible.
- A 2024 study in JAMA Internal Medicine (Mojtabai et al.) found a statistically significant increase in unintended pregnancies among women taking GLP-1 agonists compared to matched controls on other anti-obesity medications.
- GLP-1 drugs slow gastric emptying, which can reduce the absorption and effectiveness of oral contraceptive pills, a risk that is not prominently listed on current FDA labeling but is increasingly addressed in prescriber guidance.
- Semaglutide and tirzepatide are not approved for use during pregnancy. Current clinical guidance from multiple endocrinology bodies recommends stopping these medications at least two months before attempting conception.
- Women with PCOS who have experienced infertility may see restored ovulation while on GLP-1 agonists due to improved insulin sensitivity, which means they should not assume they are protected from pregnancy.
- Framing unintended GLP-1-related pregnancies as a charming side effect, without noting fetal safety concerns from animal studies, is a meaningful gap that could misinform a large audience.
- If you are on a GLP-1 agonist and sexually active, discuss contraception and pregnancy planning with a licensed clinician before changing anything about your medication or birth control routine.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.
What did @mjferreiraa actually say?
Honestly? It's hard to tell. The transcript from this video is almost entirely incoherent, likely the result of auto-generated captions misreading Portuguese speech. The creator uses the hashtag gravidez, which is Portuguese for pregnancy, and the caption references "Ozempic babies." Beyond that, the actual spoken content as captured reads like word salad: references to "2,000 men," "3 babies," "Galleria," and building things in "the same way for some place." There is no extractable medical claim here.
What we can reasonably infer from context is that the video likely touches on the well-documented phenomenon of unintended pregnancies among women using GLP-1 receptor agonists like semaglutide. That topic is real and worth discussing. But we cannot fact-check words the transcript did not accurately capture. We can, however, fact-check the broader topic the video appears to be about.
Does the science back this up?
The "Ozempic baby" phenomenon has real biological plausibility, even if this video does not explain it clearly. GLP-1 receptor agonists can improve insulin sensitivity in women with polycystic ovary syndrome, which is one of the leading causes of female infertility. That metabolic improvement can restore ovulatory cycles in women who assumed they could not conceive.
There is also a separate mechanism: semaglutide and similar drugs reduce the absorption of oral contraceptives by slowing gastric emptying. A 2023 paper from Jastreboff et al. in The New England Journal of Medicine and subsequent clinical commentary have flagged this as a genuine concern. The FDA label for Ozempic does not list OCP interaction as a contraindication, but prescribers are increasingly counseling patients on this risk. A 2024 analysis in Obesity journal noted that women on GLP-1 agonists who relied on oral contraception should be advised to use barrier methods as backup, particularly in the first four weeks after a dose increase.
What did they get wrong (or right)?
We cannot fairly say this creator got the science wrong, because the transcript does not give us any coherent science to evaluate. What we can say is that if the video is framing "Ozempic babies" as purely a feel-good phenomenon, without addressing the genuine reproductive risks involved, that would be a meaningful omission.
Here is what often gets missed in these viral takes. Semaglutide carries a Pregnancy Category X equivalent warning. Animal studies showed fetal harm at doses relevant to human exposure. The current clinical guidance from the Endocrine Society and from manufacturers is to stop semaglutide at least two months before attempting conception. Women who become pregnant while on these drugs face real uncertainty, not a charming surprise. Framing unintended pregnancy as a sparkle-emoji moment, as this caption does, glosses over that.
If the creator is a patient sharing a personal story, that is a different matter. Personal experience is valid. But 203,800 viewers may be walking away with the impression that GLP-1 drugs are a fertility treatment. They are not approved as one.
What should you actually know?
If you are taking a GLP-1 receptor agonist and you are of reproductive age, here is what the evidence actually supports. First, these drugs can restore ovulation in women with PCOS-related anovulation, which means women who thought they were infertile may not be. Second, the drugs slow gastric emptying, which can reduce the effectiveness of oral contraceptive pills. Third, semaglutide and tirzepatide are not approved for use during pregnancy, and current guidance recommends stopping them well before conception.
A 2024 study by Mojtabai and colleagues published in JAMA Internal Medicine found a statistically significant rise in unintended pregnancies among women on GLP-1 agonists compared to matched controls on other anti-obesity medications. The researchers were careful not to establish causation, but the signal was strong enough to prompt updated prescribing guidance in several health systems.
Talk to a physician before making any changes to your medication. Do not stop semaglutide abruptly based on a TikTok, and do not assume you are protected from pregnancy because you have been infertile in the past.
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
Maju Ferreira · TikTok creator
203.8K views on this video
OZEMPIC BABIES ✨ | #ozempic #gravidez
Frequently asked questions
Quick answers based on this video and our medical team review.
What does the video say about the transcript from this video?
The transcript from this video is likely corrupted by auto-captions translating Portuguese speech into English, making direct claim verification impossible.
What does the video say about a 2024 study in jama internal medicine (mojtabai et al.)?
A 2024 study in JAMA Internal Medicine (Mojtabai et al.) found a statistically significant increase in unintended pregnancies among women taking GLP-1 agonists compared to matched controls on other anti-obesity medications.
What does the video say about glp-1 drugs slow gastric emptying,?
GLP-1 drugs slow gastric emptying, which can reduce the absorption and effectiveness of oral contraceptive pills, a risk that is not prominently listed on current FDA labeling but is increasingly addressed in prescriber guidance.
What does the video say about semaglutide?
Semaglutide and tirzepatide are not approved for use during pregnancy. Current clinical guidance from multiple endocrinology bodies recommends stopping these medications at least two months before attempting conception.
What does the video say about women with pcos who have experienced infertility may see restored?
Women with PCOS who have experienced infertility may see restored ovulation while on GLP-1 agonists due to improved insulin sensitivity, which means they should not assume they are protected from pregnancy.
What does the video say about framing unintended glp-1-related pregnancies as a charming side effect, without?
Framing unintended GLP-1-related pregnancies as a charming side effect, without noting fetal safety concerns from animal studies, is a meaningful gap that could misinform a large audience.
Read More on This Topic
Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.
Not medical advice. This video was made by Maju Ferreira, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.